Alnylam Pharmaceuticals has had a prominent presence in recent news updates. The bio-tech organization reported a whopping $3B revenue for 2025 led by a 151% surge in the TTR franchise. The company's stock has also been the object of significant investor interest, with companies like Fiera Capital and NewEdge Wealth enhancing their stakes in the company. Simultaneously, organizations like ANTIPODES PARTNERS Ltd, Regeneron Pharmaceuticals Inc., and China Universal Asset Management Co. Ltd trimmed their stakes. Alnylam has recently turned profitable, which was met with mixed reactions from the market. The company announced plans to invest $250 million to bolster its manufacturing capability to meet an increased demand for RNAi therapeutics. Amidst certain financial transactions borne out of this performance, including a $2.16M cash out by Yvonne Greenstreet, Alnylam continues to project an optimistic forecast for 2026, aiming for a $5.3 billion revenue. Several analysts have a bullish outlook on the stock's potential following recent share price pullbacks, all while offering conflicting valuations for its share prices. The company also participated in the Alliance for Genomic Discovery in expanding the clinical genomic dataset.
Alnylam Pharmaceuticals News Analytics from Thu, 18 Sep 2025 07:00:00 GMT to Sat, 21 Feb 2026 11:37:42 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -2
